HOME >> BIOLOGY >> NEWS
New biosensor rapidly detects deadly foodborne pathogen

of cells present, making it possible for today's sensors to detect their presence, but it can take as long as seven days to complete a test using conventional methods, Geng said.

Other tests rely on DNA markers, but these also can take days to process, he said. That's a problem because by the time test results come back, products may already be in food suppliers' warehouses or on store shelves, he said.

Last summer, for example, a Georgia company recalled nearly 37,000 pounds of precooked chicken products that may have been contaminated by Listeria. The chicken products had been distributed to warehouses in Georgia and Arkansas, as well as to grocery stores in Maryland and New York, when the recall was issued.

"To overcome the time delay and allow for rapid detection before foods are shipped, you need to be able to detect a lower number of the pathogen cells at the processing plant," Geng said.

The ability to detect L. monocytogenes at low levels is essential because most of the foods susceptible to Listeria contamination are ready-to-eat products, which are cooked or otherwise processed for human consumption before they make it to a grocer's shelves.

"Since precooked meats have already been processed, the bulk of microorganisms that were present in the raw product have been eliminated," Bhunia said.

"We don't expect high numbers of microorganisms in processed products, so we need to be able to detect extremely low levels of contamination."

Detection at low levels also is important for another reason, Bhunia said.

"Listeria can grow at refrigeration temperatures, so if a product has a level of Listeria low enough to evade detection when it's tested at the processor, that Listeria still can grow in the home refrigerator to a level that makes it infective to people at risk."
'"/>

Contact: Jennifer Cutraro
jcutraro@purdue.edu
765-496-2050
Purdue University
5-Oct-2004


Page: 1 2 3 4

Related biology news :

1. A biosensor layered like lasagna
2. Rochester scientists develop fast-working biosensor
3. Study demonstrates rapid diagnosis of urinary tract infections with biosensor technology
4. Indo-Pacific coral reefs disappearing more rapidly than expected
5. Dipstick test could reduce risk of food poisoning by rapidly detecting spoilage
6. Fragmentation rapidly erodes Amazonian biodiversity
7. Silver bullet: UGA researchers use laser, nanotechnology to rapidly detect viruses
8. Pheromone from mothers milk may rapidly promote learning in newborn mammals
9. Fire ant-attacking fly spreading rapidly in Texas
10. Evolving defenses rapidly suppress male killers
11. New strategy rapidly identifies cancer targets

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New biosensor rapidly detects deadly foodborne pathogen

(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
(Date:4/17/2015)... Houston, TX (PRWEB) April 17, 2015 ... genomics and proteomics technologies, announced today that it ... sequencing system, an innovative multiplex PCR based targeted ... ultra-high resolution sequence analysis, that enables accurate detection ... pending Relay-PCR™ and Omega-Primer™ technologies. The company will ...
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
(Date:4/16/2015)... According to the 2014 Liberty ... source was ranked first among the leading causes ... lifting, pushing, pulling, holding, carrying, or throwing and ... David Round Company takes statistics like this very ... to develop and design equipment that prevents these ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: